Nutra Pharma Corp., a biotechnology company that is developing drugs for HIV and Multiple Sclerosis has today announced that its subsidiary, Designer Diagnostics, has received positive results from its in-vitro analysis of its Tuberculosis (TB) test kit.
“The results from this study exceeded our expectations,” explained Neil Roth, President of Designer Diagnostics, Inc. “We believe that our test kit will significantly improve speed and accuracy when treating TB patients worldwide,” he added.
Currently there are over 14.6 million people that have active TB disease with over one third of the world's population having the TB bacterium in their bodies with new infections occurring at a rate of one per second. Normal culturing methods can take as long as 10 weeks to produce results, where Designer Diagnostics test kits have shown similar results within 10 days.
“This in-vitro analysis is significant to the future growth of Designer Diagnostics,” commented Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. “Designer Diagnostics will now move into human clinical trials, the final step before bringing this product to market,” he concluded.
Designer Diagnostics is currently in discussions with the leading tuberculosis research institutes in the United States to complete human trials of the test kit technology. The Company expects to complete human trials and begin shipment within the next 4 to 6 weeks.
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The results from the Designer Diagnostics in-vitro analysis should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.